Increased Antimicrobial Resistance of Mycoplasma pneumoniae in Children in Beijing
Author Information
Author(s): Jia Xinyu, Chen Yujie, Gao Yagang, Ren Xue, Du Bing, Zhao Hanqing, Feng Yanling, Xue Guanhua, Cui Jinghua, Gan Lin, Feng Junxia, Fan Zheng, Fu Tongtong, Xu Ziying, Yu Zihui, Yang Yang, Zhao Shuo, Huang Lijuan, Ke Yuehua, Liu Chuanhe, Yan Chao, Yuan Jing
Primary Institution: Capital Institute of Pediatrics, Beijing, China
Hypothesis
The study investigates the in vitro antimicrobial susceptibility of Mycoplasma pneumoniae isolates obtained from children with pneumonia in Beijing between 2021 and 2023.
Conclusion
The study found that all Mycoplasma pneumoniae isolates exhibited 100% resistance to erythromycin and azithromycin, indicating a significant rise in antimicrobial resistance.
Supporting Evidence
- All 62 Mycoplasma pneumoniae isolates showed 100% resistance to erythromycin and azithromycin.
- The MIC of azithromycin increased significantly from 2021 to 2023.
- 76.3% of patients had severe Mycoplasma pneumoniae pneumonia.
- All isolates possessed the A2063G mutation associated with macrolide resistance.
- No resistance to tetracycline and levofloxacin was observed.
Takeaway
Doctors need to be careful when treating children with pneumonia because the germs causing it are becoming resistant to common antibiotics.
Methodology
The study analyzed the antimicrobial susceptibility of 62 Mycoplasma pneumoniae isolates using minimum inhibitory concentrations (MICs) and assessed molecular characteristics and clinical manifestations.
Limitations
The study analyzed a limited number of isolates, which may not comprehensively represent the actual situation in Beijing.
Participant Demographics
Children hospitalized with Mycoplasma pneumoniae pneumonia in Beijing.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website